By NextBestFitEasy access to medication treatment
Any clinician can prescribe buprenorphine; methadone available in pharmacies and primary care.
Reduces overdose deaths.
Review ledgerHow this path connects
This path
Easy access to medication treatment
Concrete changes if chosen
What would actually have to change in law, agencies, payment rules, or systems.
- Allow any clinician to prescribe buprenorphine
- Allow methadone in pharmacies and primary care
Effects
Each effect has its own page: the evidence, the case that it is or isn't a real cost, and whom it affects.
What it fixes
- Overdose crisis and gaps in addiction treatment
Allowing clinicians to prescribe buprenorphine and offering methadone in pharmacies and primary care reduces overdose deaths. Treatment in ordinary clinics also reduces stigma.
What it creates or worsens
- Fraud and improper payments
Broader access to buprenorphine and methadone raises concerns about medication diversion.
- Faces political, industry, or legal opposition
Some clinicians are reluctant to prescribe medication for addiction despite broader prescribing access.
Who's affected
Who gains
- People with substance use disorders and affected communities
- Overdose crisis and gaps in addiction treatment: Overdoses, treatment restrictions, and coverage gaps harm people and their families.
- Family caregivers and affected families
- Overdose crisis and gaps in addiction treatment: Overdoses, treatment restrictions, and coverage gaps harm people and their families.
- Fraudulent operators and cybercriminals
- Fraud and improper payments: Fraudulent providers receive improper health payments.
Who loses
- Hospitals, clinics, and care organizations
- Overdose crisis and gaps in addiction treatment: Unregulated treatment operators benefit from the treatment system’s gaps.
- Fraudulent operators and cybercriminals
- Overdose crisis and gaps in addiction treatment: Illicit drug markets benefit from ongoing substance use.
- Taxpayers and public budgets
- Fraud and improper payments: Fraud and improper payments consume public funds and premiums.
- People with employer coverage
- Fraud and improper payments: Fraud and improper payments consume public funds and premiums.
Where it has been tried
- France, Canada: Buprenorphine and methadone widely available.
- France: The French study reported approximately 65,000 buprenorphine patients annually—about ten times the number treated under restrictive methadone policies—and a coincident 79% decline in overdose deaths from 1995 to 1999.